Intravesical rAd-IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. [PDF]
, 2017 Purpose Many patients with high-risk non-muscle-invasive bladder cancer (NMIBC) are either refractory to bacillus Calmette-Guerin (BCG) treatment or may experience disease relapse.
Bivalacqua, Trinity J +23 more
core +2 more sources
Bacterial outer membrane vesicles and vaccine applications [PDF]
, 2014 Vaccines based on outer membrane vesicles (OMV) were developed more than 20 years ago against Neisseria meningitidis serogroup B. These nano-sized structures exhibit remarkable potential for immunomodulation of immune responses and delivery of “self ...
Acevedo, Reinaldo +10 more
core +6 more sources
Use of recombinant virus replicon particles for vaccination against Mycobacterium ulcerans disease [PDF]
, 2015 Buruli ulcer, caused by infection with Mycobacterium ulcerans, is a necrotizing disease of the skin and subcutaneous tissue, which is most prevalent in rural regions of West African countries.
Bolz, Miriam +3 more
core +3 more sources
Screening vaccine formulations for biological activity using fresh human whole blood. [PDF]
, 2014 Understanding the relevant biological activity of any pharmaceutical formulation destined for human use is crucial. For vaccine-based formulations, activity must reflect the expected immune response, while for non-vaccine therapeutic agents, such as ...
Aboutorabian, Sepideh +9 more
core +1 more source
Vaccines, 2023 Bacillus Calmette–Guérin (BCG) is the only widely used prophylactic tuberculosis (TB) vaccine that can prevent severe TB in infants. However, it provides poor protection in adults, and therefore, there is ongoing research into new TB vaccines and ...
Ruihuan Wang +11 more
doaj +1 more source
The immunogenicity of recombinant Mycobacterium smegmatis bearing BCG genes [PDF]
Microbiology, 1995 SUMMARYSpecific pathogen-free C57BL/6 mice infected with recombinantMycobacterium smegmatis(rM. smegmatis) bearing BCG genes showed increased splenic survival compared to those receiving the vector control (plasmid DNA only). The mouse-passaged rM. smegmatis(J3R) survived in peritoneal macrophages better than the vector control, regardless of whether ...
Valeria, Falcone +3 more
openaire +2 more sources
Mucosal delivery of tuberculosis vaccines: a review of current approaches and challenges. [PDF]
, 2019 Introduction: Tuberculosis (TB) remains a major health threat and it is now clear that the current vaccine, BCG, is unable to arrest the global TB epidemic. A new vaccine is needed to either replace or boost BCG so that a better level of protection could
Barclay WR +8 more
core +1 more source
cDNA-RNA subtractive hybridization reveals increased expression of mycocerosic acid synthase in intracellular Mycobacterium bovis BCG. [PDF]
, 2001 Identifying genes that are differentially expressed by Mycobacterium bovis BCG after phagocytosis by macrophages will facilitate the understanding of the molecular mechanisms of host cell-intracellular pathogen interactions. To identify such genes a cDNA-
Centre Gunnels Wood +7 more
core +3 more sources
The bacillary and macrophage response to hypoxia in tuberculosis and the consequences for T cell antigen recognition [PDF]
, 2016 M. tuberculosis is a facultative anaerobe and its characteristic pathological hallmark, the granuloma, exhibits hypoxia in humans and in most experimental models. Thus the host and bacillary adaptation to hypoxia is of central importance in understanding
Barry III, CE +5 more
core +1 more source
Recombinant BCG expressing Mycobacterium tuberculosis major extracellular proteins [PDF]
Microbes and Infection, 2005 rBCG30, the first vaccine against tuberculosis demonstrated more potent than BCG in preclinical studies, is the prototype of a class of vaccines that utilize BCG as a host organism for expressing and secreting Mycobacterium tuberculosis major extracellular proteins.
openaire +3 more sources